FDA Decree Results into Shares Fall for Genzyme
Abstract:Declaration made by the Food and Drug Administration to hire a third-part inspector in order to keep up with quality-control standards, made shares of biotech firm Genzyme fell 4 percent to $55.25 in afternoon trading on Wednesday.
Trending Compliance Trainings
Excel Spreadsheets; Ensuring Data Integrity and 21 CFR Part 11 Compliance
By - David Nettleton
On Demand Access Anytime
By - David Nettleton
On Demand Access Anytime
Water System Investigation "How-To's" and Example Case Studies
By - T.C Soli
On Demand Access Anytime
By - T.C Soli
On Demand Access Anytime
Solutions for Addressing Fungal and Bacterial Spore Outbreaks in Pharmaceutical, Biotech, and Medical Device Operations
By - Jim Polarine
On Demand Access Anytime
By - Jim Polarine
On Demand Access Anytime
How to Achieve a Compliant and Effective Cleanroom Design and Facility Validation
By - Charity Ogunsanya
On Demand Access Anytime
By - Charity Ogunsanya
On Demand Access Anytime
FDA Compliance and Clinical Trial Computer System Validation
By - Carolyn Troiano
On Demand Access Anytime
By - Carolyn Troiano
On Demand Access Anytime
You Recently Viewed
